Telehealth use in patients with type 2 diabetes in Australian general practice during the COVID-19 pandemic: a retrospective cohort study
The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown. To evaluate the upta...
Saved in:
Published in | BJGP open Vol. 6; no. 3; p. BJGPO.2021.0200 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Royal College of General Practitioners
01.09.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 2398-3795 2398-3795 |
DOI | 10.3399/BJGPO.2021.0200 |
Cover
Loading…
Abstract | The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown.
To evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations.
This exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019-February 2020 was compared with a pandemic period from March 2020-February 2021. Patients diagnosed with T2DM before March 2018 were included.
Telehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth.
Of 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only.
Telehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations. |
---|---|
AbstractList | The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown.
To evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations.
This exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019-February 2020 was compared with a pandemic period from March 2020-February 2021. Patients diagnosed with T2DM before March 2018 were included.
Telehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth.
Of 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only.
Telehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations. The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown.BACKGROUNDThe Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown.To evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations.AIMTo evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations.This exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019-February 2020 was compared with a pandemic period from March 2020-February 2021. Patients diagnosed with T2DM before March 2018 were included.DESIGN & SETTINGThis exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019-February 2020 was compared with a pandemic period from March 2020-February 2021. Patients diagnosed with T2DM before March 2018 were included.Telehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth.METHODTelehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth.Of 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only.RESULTSOf 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only.Telehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations.CONCLUSIONTelehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations. Background: The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the COVID-19 pandemic. The uptake of telehealth by patients with type 2 diabetes (T2DM) for consulting with GPs is unknown. Aim: To evaluate the uptake of telehealth consultations and associated patient characteristics in Australian general practice, including the frequency of haemoglobin A1c (HbA1c) tests and change in HbA1c levels by telehealth use, compared with guideline recommendations. Design & setting: This exploratory study used electronic patient data from approximately 800 general practices in Victoria and New South Wales (NSW), Australia. A pre-COVID-19 period from March 2019–February 2020 was compared with a pandemic period from March 2020–February 2021. Patients diagnosed with T2DM before March 2018 were included. Method: Telehealth uptake patterns were examined overall and by patient characteristics. Generalised estimating equation models were used to examine patient probability of 6-monthly HbA1c testing and change in HbA1c levels, comparing between patients who did and patients who did not use telehealth. Results: Of 57 916 patients, 80.8% had telehealth consultations during the pandemic period. Telehealth consultations were positively associated with patients with T2DM who were older, female, had chronic kidney disease (CKD), prescribed antidiabetic medications, and living in remote areas. No significant difference was found in 6-monthly HbA1c testing and HbA1c levels between telehealth users and patients who had face-to-face consultations only. Conclusion: Telehealth GP consultations were well utilised by patients with T2DM. Diabetes monitoring care via telehealth is as effective as face-to-face consultations. |
Author | Pearce, Christopher Imai, Chisato Georgiou, Andrew Badrick, Tony Thomas, Judith Hardie, Rae-Anne |
Author_xml | – sequence: 1 givenname: Chisato orcidid: 0000-0002-0080-1487 surname: Imai fullname: Imai, Chisato – sequence: 2 givenname: Judith orcidid: 0000-0002-0715-9124 surname: Thomas fullname: Thomas, Judith – sequence: 3 givenname: Rae-Anne orcidid: 0000-0003-4868-4045 surname: Hardie fullname: Hardie, Rae-Anne – sequence: 4 givenname: Christopher orcidid: 0000-0001-5371-8196 surname: Pearce fullname: Pearce, Christopher – sequence: 5 givenname: Tony orcidid: 0000-0003-4846-9134 surname: Badrick fullname: Badrick, Tony – sequence: 6 givenname: Andrew orcidid: 0000-0002-7619-3668 surname: Georgiou fullname: Georgiou, Andrew |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35640964$$D View this record in MEDLINE/PubMed |
BookMark | eNp1Uk1v1DAQtVARLaVnbshHLtn6K07MAaksUBZVWg6Fq-U4k11X2TjYTtH-BP41TrdULRKyrBmN37zxzLyX6GjwAyD0mpIF50qdf_h6-W29YITRBWGEPEMnjKu64JUqjx75x-gsxhtCCFVUCiFeoGNeSkGUFCfo9zX0sAXTpy2eImA34NEkB0OK-JfLwbQfATPcOtNAgjgDLqaYgumdGfAGBsguHoOxyVnA7RTcsMFpC3i5_rH6WFCVCYcWds6-wwYHSMHHETL6FrD1Wx8Sjmlq96_Q8870Ec7u7Sn6_vnT9fJLcbW-XC0vrgorSpWKqjGdknXTGmmhpZKXVcuhYh1ISkhVq1rWlehqqjpLaso40JJlI8qOg-Kcn6LVgbf15kaPwe1M2GtvnL4L-LDRJuReetCsqQC4kIITlW_XEKFq1nayoo3qSpK53h-4xqnZQWvz2PI0npA-fRncVm_8rc4dkErOBG_vCYL_OUFMeueihb43A_gpaiYrxudTZ-ibx7UeivzdZQacHwA2TzgG6B4glOhZMPpOMHoWjJ4FkzPKfzKsS3n7fv6s6_-b9wfU_8RW |
CitedBy_id | crossref_primary_10_2196_42607 crossref_primary_10_56294_saludcyt2024750 crossref_primary_10_3399_BJGPO_2022_0120 crossref_primary_10_2196_42753 crossref_primary_10_1186_s41043_023_00418_x crossref_primary_10_1111_jocn_16805 crossref_primary_10_3399_BJGPO_2022_0117 |
Cites_doi | 10.1016/j.mpmed.2018.10.002 10.1186/s12874-018-0519-5 10.1089/tmj.2018.0128 10.1111/imj.15441 10.1177/1357633X20985763 10.1001/jama.280.19.1690 10.2522/ptj.20080020 10.1016/j.ijmedinf.2020.104189 10.1111/jdi.13546 10.1097/MD.0000000000000312 10.1177/1932296820947094 10.3389/fpubh.2021.648009 10.1016/j.ijmedinf.2021.104483 10.3390/diabetology2010001 10.1016/j.diabres.2020.108298 10.1136/bmjhci-2019-100009 10.1177/0036933020946336 10.1159/000509000 10.1210/jendso/bvab048.710 10.1016/j.ijmedinf.2018.07.007 10.3904/kjim.2020.464 |
ContentType | Journal Article |
Copyright | Copyright © 2022, The Authors. Copyright © 2022, The Authors 2022 |
Copyright_xml | – notice: Copyright © 2022, The Authors. – notice: Copyright © 2022, The Authors 2022 |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3399/BJGPO.2021.0200 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ (Directory of Open Access Journals) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2398-3795 |
ExternalDocumentID | oai_doaj_org_article_2b7ee3464309430fb04982df671b9f50 PMC9680760 35640964 10_3399_BJGPO_2021_0200 |
Genre | Journal Article |
GroupedDBID | 5VS AAYXX ACDUE ADBBV AIJKH ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV CITATION EBS EIHBH GROUPED_DOAJ HYE M~E OK1 RPM NPM 7X8 5PM |
ID | FETCH-LOGICAL-c459t-7baf968bda6ced16357d3e72fe610078986874f819fc08123e15212345f3e9333 |
IEDL.DBID | DOA |
ISSN | 2398-3795 |
IngestDate | Wed Aug 27 01:27:33 EDT 2025 Thu Aug 21 18:39:37 EDT 2025 Fri Jul 11 10:32:05 EDT 2025 Thu Apr 03 06:59:36 EDT 2025 Tue Jul 01 02:53:00 EDT 2025 Thu Apr 24 23:11:17 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | COVID-19 telemedicine diabetes mellitus, type 2 general practice |
Language | English |
License | Copyright © 2022, The Authors. This article is Open Access: CC BY license (https://creativecommons.org/licenses/by/4.0/) |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c459t-7baf968bda6ced16357d3e72fe610078986874f819fc08123e15212345f3e9333 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-0080-1487 0000-0002-7619-3668 0000-0002-0715-9124 0000-0001-5371-8196 0000-0003-4868-4045 0000-0003-4846-9134 |
OpenAccessLink | https://doaj.org/article/2b7ee3464309430fb04982df671b9f50 |
PMID | 35640964 |
PQID | 2672323238 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2b7ee3464309430fb04982df671b9f50 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9680760 proquest_miscellaneous_2672323238 pubmed_primary_35640964 crossref_primary_10_3399_BJGPO_2021_0200 crossref_citationtrail_10_3399_BJGPO_2021_0200 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-09-01 |
PublicationDateYYYYMMDD | 2022-09-01 |
PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | BJGP open |
PublicationTitleAlternate | BJGP Open |
PublicationYear | 2022 |
Publisher | Royal College of General Practitioners |
Publisher_xml | – name: Royal College of General Practitioners |
References | 2022092817501035000_6.3.BJGPO.2021.0200.21 2022092817501035000_6.3.BJGPO.2021.0200.20 2022092817501035000_6.3.BJGPO.2021.0200.25 2022092817501035000_6.3.BJGPO.2021.0200.24 2022092817501035000_6.3.BJGPO.2021.0200.23 2022092817501035000_6.3.BJGPO.2021.0200.22 2022092817501035000_6.3.BJGPO.2021.0200.9 2022092817501035000_6.3.BJGPO.2021.0200.18 2022092817501035000_6.3.BJGPO.2021.0200.8 2022092817501035000_6.3.BJGPO.2021.0200.17 2022092817501035000_6.3.BJGPO.2021.0200.16 2022092817501035000_6.3.BJGPO.2021.0200.15 2022092817501035000_6.3.BJGPO.2021.0200.5 2022092817501035000_6.3.BJGPO.2021.0200.4 2022092817501035000_6.3.BJGPO.2021.0200.7 2022092817501035000_6.3.BJGPO.2021.0200.6 2022092817501035000_6.3.BJGPO.2021.0200.19 2022092817501035000_6.3.BJGPO.2021.0200.1 2022092817501035000_6.3.BJGPO.2021.0200.3 2022092817501035000_6.3.BJGPO.2021.0200.2 2022092817501035000_6.3.BJGPO.2021.0200.10 2022092817501035000_6.3.BJGPO.2021.0200.31 2022092817501035000_6.3.BJGPO.2021.0200.30 2022092817501035000_6.3.BJGPO.2021.0200.14 2022092817501035000_6.3.BJGPO.2021.0200.13 2022092817501035000_6.3.BJGPO.2021.0200.12 2022092817501035000_6.3.BJGPO.2021.0200.11 2022092817501035000_6.3.BJGPO.2021.0200.29 2022092817501035000_6.3.BJGPO.2021.0200.28 2022092817501035000_6.3.BJGPO.2021.0200.27 2022092817501035000_6.3.BJGPO.2021.0200.26 |
References_xml | – ident: 2022092817501035000_6.3.BJGPO.2021.0200.3 doi: 10.1016/j.mpmed.2018.10.002 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.22 doi: 10.1186/s12874-018-0519-5 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.30 doi: 10.1089/tmj.2018.0128 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.8 doi: 10.1111/imj.15441 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.11 doi: 10.1177/1357633X20985763 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.4 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.23 doi: 10.1001/jama.280.19.1690 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.19 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.17 doi: 10.2522/ptj.20080020 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.26 doi: 10.1016/j.ijmedinf.2020.104189 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.10 doi: 10.1111/jdi.13546 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.29 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.31 doi: 10.1097/MD.0000000000000312 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.6 doi: 10.1177/1932296820947094 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.27 doi: 10.3389/fpubh.2021.648009 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.21 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.25 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.13 doi: 10.1016/j.ijmedinf.2021.104483 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.2 doi: 10.3390/diabetology2010001 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.18 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.16 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.5 doi: 10.1016/j.diabres.2020.108298 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.14 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.15 doi: 10.1136/bmjhci-2019-100009 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.1 doi: 10.1177/0036933020946336 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.28 doi: 10.1159/000509000 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.12 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.7 doi: 10.1210/jendso/bvab048.710 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.24 doi: 10.1016/j.ijmedinf.2018.07.007 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.20 – ident: 2022092817501035000_6.3.BJGPO.2021.0200.9 doi: 10.3904/kjim.2020.464 |
SSID | ssj0001916444 |
Score | 2.2486746 |
Snippet | The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in response to the... Background: The Australian government introduced temporary government-subsidised telehealth service items (phone and video-conference) in mid-March 2020 in... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | BJGPO.2021.0200 |
SubjectTerms | covid-19 diabetes mellitus, type 2 general practice telemedicine |
Title | Telehealth use in patients with type 2 diabetes in Australian general practice during the COVID-19 pandemic: a retrospective cohort study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35640964 https://www.proquest.com/docview/2672323238 https://pubmed.ncbi.nlm.nih.gov/PMC9680760 https://doaj.org/article/2b7ee3464309430fb04982df671b9f50 |
Volume | 6 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQT1wQiBbCRzVIPXAJ3diO7fRGC6VUgnJoUW9W7NhQqcqi3eyP6L9mxk6WXQTignJLbMfyjDVvxjPPjB2gkYtBtabUwvMSTYAr2zhzpZh1vhJ-1jYp3vHpszq7kufX9fXGVV-UE5bpgfPCHXKnQxASx6QcuFl0CGkN76LSlWti9tbR5m04Uym6gqhHSpm5fAQa4cPj8w9fLtAf5MTRSfVsG2YosfX_CWL-nim5YXpOH7IHI2aEt3muj9i90D9md5doMHIVI6yWAW56GDlSl0DBVaDgKnCYgqvU4FdgA75lummYqqQg1ysC4kE4ufj68V1ZNThgn5Lnj6CFRRgW86kuE-he3cUAiZx2l12dvr88OSvHexVKL-tmKLVrY6OM61rlQ1cRI10nguYoNMqZMI1RRsuIWCF6RAxchCpV-Mo6itAIIfbYTj_vw1MGvhZd28kKO9USwYDrjDMyeonyb6TTBXszLbP1I-k43X1xa9H5ILnYJBdLcrEkl4K9Xnf4kfk2_t70mOS2bkZE2ekFqo8d1cf-S30K9mqSusWNRaclbR_mq6XlSiPaxMcU7EnWgvWvRK3QL1ayYHpLP7bmsv2lv_meyLtx4ekw9Nn_mPxzdp9TNUZKeXvBdobFKrxEjDS4_bQdfgL2ng4H |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Telehealth+use+in+patients+with+type+2+diabetes+in+Australian+general+practice+during+the+COVID-19+pandemic%3A+a+retrospective+cohort+study&rft.jtitle=BJGP+open&rft.au=Imai%2C+Chisato&rft.au=Thomas%2C+Judith&rft.au=Hardie%2C+Rae-Anne&rft.au=Pearce%2C+Christopher&rft.date=2022-09-01&rft.issn=2398-3795&rft.eissn=2398-3795&rft.volume=6&rft.issue=3&rft_id=info:doi/10.3399%2FBJGPO.2021.0200&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2398-3795&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2398-3795&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2398-3795&client=summon |